Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

PCV13i

Phase 3Biologic

CanSino Biologics Inc.

1

Indications

1

Total Trials

1

Active Trials

0

Competitors

Pipeline

Status by Indication[3][1]

Indication

Pneumococcal InfectionsActive, not recruiting

Pneumococcal InfectionsPhase 3

Active, not recruiting

Timeline

Expected Milestones

Q2 2028

Phase 3Active, not recruiting

Pneumococcal Infections

NCT07017777

Clinical

Trials by Indication[1]

Pneumococcal Infections1 trial

A Phase III, Observer-blind, Randomized Controlled Trial to Evaluate the Immunogenicity and Safety of 13-valent Pneumococcal Conjugate Vaccine (PCV13i) in Healthy Infants Aged 2 Months (Minimum 6 Weeks)

Active, not recruiting· CanSino Biologics Inc. logo

CanSino Biologics Inc.·Phase 3·NCT07017777·600 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for PCV13i. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — PCV13i compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for PCV13i. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — CanSino Biologics Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Phase 3[1]
Company: CanSino Biologics Inc.

Related News